{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:50Z","timestamp":1789014530412,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41375-021-01294-2","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:03:42Z","timestamp":1622030622000},"page":"2445-2459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hernandez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4035","authenticated-orcid":false,"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-9023","authenticated-orcid":false,"given":"H.","family":"Joachim Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Ditschkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal T.","family":"Moonim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1294_CR1","doi-asserted-by":"crossref","unstructured":"McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659\u201368.","DOI":"10.3324\/haematol.2018.206151"},{"key":"1294_CR2","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia 2015;29:2126\u201333.","journal-title":"Leukemia"},{"key":"1294_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.15407","volume":"182","author":"DP McLornan","year":"2018","unstructured":"McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, et al. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018;182:418\u201322.","journal-title":"Br J Haematol."},{"key":"1294_CR4","doi-asserted-by":"crossref","unstructured":"McLornan DP, Sirait T, Hern\u00e1ndez-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Curr Res Transl Med. 2020;69:103267.","DOI":"10.1016\/j.retram.2020.08.003"},{"key":"1294_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","volume":"25","author":"D McLornan","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/sj.bmt.1703389","volume":"29","author":"S Wolff","year":"2002","unstructured":"Wolff S. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29:545\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR7","doi-asserted-by":"crossref","unstructured":"Valc\u00e1rcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kr\u00f6ger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. p. 307\u201313. http:\/\/link.springer.com\/10.1007\/978-3-030-02278-5_41.","DOI":"10.1007\/978-3-030-02278-5_41"},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","volume":"48","author":"R Olsson","year":"2013","unstructured":"Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:537\u201343.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","volume":"35","author":"JC Hern\u00e1ndez-Boluda","year":"2021","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Kr\u00f6ger N, Beelen D, Robin M, Bornh\u00e4user M, et al. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2021;35:215\u201324.","journal-title":"Leukemia."},{"key":"1294_CR10","doi-asserted-by":"crossref","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N, editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International Publishing; 2019. http:\/\/link.springer.com\/10.1007\/978-3-030-02278-5.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"1294_CR11","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbmt.2016.08.029","volume":"22","author":"A Keyzner","year":"2016","unstructured":"Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, et al. Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis. Biol Blood Marrow Transplant. 2016;22:2180\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.bbmt.2014.05.016","volume":"20","author":"A Stasia","year":"2014","unstructured":"Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1440\u20133.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bbmt.2013.11.034","volume":"20","author":"E Klyuchnikov","year":"2014","unstructured":"Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20:382\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bmt.2016.98","volume":"51","author":"H Alchalby","year":"2016","unstructured":"Alchalby H, Yunus D-R, Zabelina T, Ayuk F, Kr\u00f6ger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016;51:1223\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","volume":"25","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1898\u2013907.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR16","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3324\/haematol.2019.226340","volume":"105","author":"M Cuadrado","year":"2019","unstructured":"Cuadrado M, Richard M, Szydlo M, Watts M, Patel N, Renshaw H, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 2019;105:2639\u201346.","journal-title":"Haematologica."},{"key":"1294_CR17","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood."},{"key":"1294_CR18","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica."},{"key":"1294_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189\u201399.","journal-title":"Leukemia."},{"key":"1294_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0302-9","volume":"10","author":"T Jain","year":"2020","unstructured":"Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10:36.","journal-title":"Blood Cancer J"},{"key":"1294_CR21","doi-asserted-by":"publisher","unstructured":"Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, et al. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.223503.","DOI":"10.3324\/haematol.2019.223503"},{"key":"1294_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.bbmt.2020.07.013","volume":"26","author":"HJ Deeg","year":"2020","unstructured":"Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, et al. Early mixed lymphoid donor\/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2020;26:2197\u2013203.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.bbmt.2006.07.008","volume":"12","author":"GE Sale","year":"2006","unstructured":"Sale GE, Deeg HJ, Porter BA. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant. 2006;12:1285\u201394.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bmt.2014.323","volume":"50","author":"R Tamari","year":"2015","unstructured":"Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, et al. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015;50:628\u201336.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR25","first-page":"879","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol. 2005;20:879\u201389.","journal-title":"Histol Histopathol"},{"key":"1294_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","volume":"20","author":"N Kr\u00f6ger","year":"2014","unstructured":"Kr\u00f6ger N, Zabelina T, Alchalby H, St\u00fcbig T, Wolschke C, Ayuk F, et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2014;20:812\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MM, Bloomfield CD, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013406.","journal-title":"Blood."},{"key":"1294_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.12871","volume":"68","author":"HM Kvasnicka","year":"2016","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis\u2014a consensus-based study. Histopathology. 2016;68:905\u201315.","journal-title":"Histopathology."},{"key":"1294_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.12075","volume":"160","author":"AJ Bench","year":"2013","unstructured":"Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2013;160:25\u201334.","journal-title":"Br J Haematol"},{"key":"1294_CR30","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233\u201342.","journal-title":"Blood."},{"key":"1294_CR31","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","volume":"23","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:1095\u2013101.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","volume":"3","author":"H Ali","year":"2019","unstructured":"Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv. 2019;3:83\u201395.","journal-title":"Blood Adv"},{"key":"1294_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","volume":"25","author":"R Tamari","year":"2019","unstructured":"Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, et al. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019;25:1142\u201351.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.bbmt.2020.03.007","volume":"26","author":"EA Stevens","year":"2020","unstructured":"Stevens EA, Jenkins IC, Beppu LW, Zhang Q, Salit R, Loeb KR, et al. Targeted sequencing improves DIPSS-Plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020;26:1371\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR35","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"1294_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","volume":"5","author":"D Luque Paz","year":"2021","unstructured":"Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto J-C, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5:1442\u201351.","journal-title":"Blood Adv"},{"key":"1294_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, J\u00e4kel N, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722\u20138.","journal-title":"Haematologica."},{"key":"1294_CR38","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.1016\/j.bbmt.2016.12.217","volume":"23","author":"MV Shah","year":"2017","unstructured":"Shah MV, Patel KP, Luthra R, Shamanna RK, Mehrotra M, Champlin RE, et al. Real time PCR detects relapse of JAK2 V617F myelofibrosis earlier than pyrosequencing after allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23:S298\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2017.157","volume":"52","author":"C Wolschke","year":"2017","unstructured":"Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, et al. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant. 2017;52:1526\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR40","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831\u20138.","journal-title":"Blood."},{"key":"1294_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1046\/j.1365-2141.2000.01826.x","volume":"108","author":"JL Byrne","year":"2000","unstructured":"Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das-Gupta E, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a \u2018graft vs. myelofibrosis\u2019 effect. Br J Haematol. 2000;108:430\u20133.","journal-title":"Br J Haematol"},{"key":"1294_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.bmt.1702568","volume":"26","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26:697\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bjh.12013","volume":"159","author":"E Klyuchnikov","year":"2012","unstructured":"Klyuchnikov E, Holler E, Bornh\u00e4user M, Kobbe G, Nagler A, Shimoni A, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. 2012;159:172\u201381.","journal-title":"Br J Haematol"},{"key":"1294_CR44","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","volume":"113","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, et al. JAK2-V617F\u2013triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113:1866\u20138.","journal-title":"Blood."},{"key":"1294_CR45","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","volume":"103","author":"KS Peggs","year":"2004","unstructured":"Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548\u201356.","journal-title":"Blood."},{"key":"1294_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","volume":"105","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105:47\u201358.","journal-title":"Haematologica."},{"key":"1294_CR47","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1182\/blood.V128.22.1948.1948","volume":"128","author":"D Janson","year":"2016","unstructured":"Janson D, Ayuk FA, Wolschke C, Christopeit M, Badbaran A, von Pein U-M, et al. Ruxolitinib for myelofibrosis patients relapsing after allogeneic hematopoietic transplantation. Blood. 2016;128:1948.","journal-title":"Blood."},{"key":"1294_CR48","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood-2019-125802","volume":"134","author":"M Nabergoj","year":"2019","unstructured":"Nabergoj M, Wang J, Robin M, Kr\u00f6ger N, Angelucci E, Poire X, et al. Outcomes following second allogenic haematopoietic Cell transplantation in patients with myelofibrosis: a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT. Blood. 2019;134:698.","journal-title":"Blood."},{"key":"1294_CR49","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.3390\/cancers12113098","volume":"12","author":"IK Atagunduz","year":"2020","unstructured":"Atagunduz IK, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, et al. Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis. Cancers. 2020;12:3098.","journal-title":"Cancers."},{"key":"1294_CR50","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.bbmt.2020.09.006","volume":"26","author":"IK Atagunduz","year":"2020","unstructured":"Atagunduz IK, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kr\u00f6ger N. Incidence and outcome of late relapse after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2020;26:2279\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Mauff K, Kr\u00f6ger N, Robin M, Beelen D, Beauvais D, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:69\u201379.","journal-title":"Am J Hematol"},{"key":"1294_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1586\/eci.11.24","volume":"7","author":"A Petrovic","year":"2011","unstructured":"Petrovic A, Hale G. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Expert Rev Clin Immunol. 2011;7:515\u201327.","journal-title":"Expert Rev Clin Immunol"},{"key":"1294_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","volume":"150","author":"M Robin","year":"2010","unstructured":"Robin M, Esp\u00e9rou H, De Latour RP, Petropoulou AD, Xhaard A, Ribaud P, et al. correspondence: splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis: correspondence. Br J Haematol. 2010;150:721\u20134.","journal-title":"Br J Haematol"},{"issue":"Mar","key":"1294_CR54","first-page":"380","volume":"47","author":"For the Nordic MPD Study Group, Abelsson J, Merup M, Birgeg\u00e5rd G, WeisBjerrum O, Brinch L, et al.","year":"2012","unstructured":"For the Nordic MPD Study Group, Abelsson J, Merup M, Birgeg\u00e5rd G, WeisBjerrum O, Brinch L, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012;47(Mar):380\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1294_CR55","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.bulcan.2018.10.002","volume":"106","author":"J De Vos","year":"2019","unstructured":"De Vos J, Baudoux E, Bay J-O, Calmels B, Cras A, El Cheikh J, et al. Injections de lymphocytes du donneur (DLI): recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC). Bull du Cancer. 2019;106:S35\u20139.","journal-title":"Bull du Cancer."}],"updated-by":[{"DOI":"10.1038\/s41375-021-01395-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01294-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:11:17Z","timestamp":1633007477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01294-2","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-021-01395-y","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-021-01395-y","URL":"https:\/\/doi.org\/10.1038\/s41375-021-01395-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}